Phaseline

Targets › BMX

BMX (Cytoplasmic tyrosine-protein kinase BMX): drug programs, companies and trials

1 program from 1 company in 11 trials: 6 Phase 3, 5 Phase 2; Immunology, Metabolic and endocrine; next expected readout Dec 2026.

Non-receptor tyrosine kinase that plays central but diverse modulatory roles in various signaling processes involved in the regulation of actin reorganization, cell migration, cell proliferation and survival, cell adhesion, and apoptosis. Participates in signal transduction stimulated by growth factor receptors, cytokine receptors, G protein-coupled receptors, antigen receptors and integrins. (UniProt, P51813)

Open in Phaseline: the race on BMX, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PfizerRitlecitinib
Tyrosine-protein kinase JAK3 inhibitor; TEC family kinase inhibitor
JAK3, ITK, BMX, TEC, TXKPhase 3Severe Alopecia Areata; Vitiligo; Stable Nonsegmental Vitiligo; Alopecia Areata …Dec 2026

Conditions

Severe Alopecia Areata (2) Vitiligo (2) Alopecia Areata (2) Stable Nonsegmental Vitiligo (1) Hidradenitis Suppurativa (1) Chronic Spontaneous Urticaria (1) Keloid (1) Diabetes Mellitus, Type 1 (1)

Modalities

small molecule (1)

Companies

Pfizer (1)

Related targets

JAK3 (1) ITK (1) TEC (1) TXK (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.